Escort aptamers: a delivery service for diagnosis and therapy

Hicke, Brian J.; Stephens, Andrew

doi:10.1172/jci11324

Cited by 150 publications

(110 citation statements)

References 25 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…This aptamer not only validates Ang2 as a target for other inhibition strategies but may also be adapted itself as a therapeutic agent. Like monoclonal antibodies, many of which have successfully entered the clinical realm, aptamers bind their targets with high affinity and specificity, and the attachment of fluorescent, radioactive, or other functional groups may expand the repertoire of potential applications for these versatile molecules (42). However, unlike monoclonal antibodies, oligonucleotides are intrinsically poor antigens, and they are amenable to large-scale chemical synthesis.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2

White

Shan²,

Rusconi³

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

152

134

View full text Add to dashboard Cite

Angiopoietin-2 (Ang2) appears to be a naturally occurring antagonist of the endothelial receptor tyrosine kinase Tie2, an important regulator of vascular stability. Destabilization of the endothelium by Ang2 is believed to potentiate the actions of proangiogenic growth factors. To investigate the specific role of Ang2 in the adult vasculature, we generated a nuclease-resistant RNA aptamer that binds and inhibits Ang2 but not the related Tie2 agonist, angiopoietin-1. Local delivery of this aptamer but not a partially scrambled mutant aptamer inhibited basic fibroblast growth factormediated neovascularization in the rat corneal micropocket angiogenesis assay. These in vivo data directly demonstrate that a specific inhibitor of Ang2 can act as an antiangiogenic agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2

White

Shan²,

Rusconi³

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

152

134

View full text Add to dashboard Cite

show abstract

“…Because aptamers are capable of binding with high specificity to their ligands at low nano-to picomolar dissociation constants they can be used as molecular drugs for both basic research and clinical purposes 44,45,46,47,48 .…”

Section: Discussionmentioning

confidence: 99%

Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy

Zhou

et al. 2007

Nat Prec

View full text Add to dashboard Cite

SummaryThe successful use of small interfering RNAs (siRNAs) for therapeutic purposes requires safe and efficient delivery to specific cells and tissues. Here we demonstrate cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer. The envelope glycoprotein is expressed on the surface of HIV-1 infected cells, allowing binding and interalization of the aptamer-siRNA chimeric molecules. We demonstrate that the anti-gp120 aptamer-siRNA chimera is specifically taken up by cells expressing HIV-1 gp120, and the appended siRNA is processed by Dicer, releasing an anti-tat/rev siRNA which in turn inhibits HIV replication. We show for the first time a dual functioning aptamer-siRNA chimera in which both the aptamer and the siRNA portions have potent anti-HIV activities and that gp120 expressed on the surface of HIV infected cells can be used for aptamer mediated delivery of anti-HIV siRNAs.RNA interference (RNAi) is a process of sequence-specific post-transcriptional gene silencing triggered by small interfering RNAs (siRNA). The silencing is sequence specific and one of the two strands of the siRNA guides the RNA induced silencing complex (RISC) to the complementary target, resulting in cleavage and subsequent destruction of the target RNA 1 . RNAi is rapidly becoming one of the methods of choice for gene function studies, and is also being exploited for therapeutic applications 2, 3 . The

show abstract

“…35 With the dawn of new millennium, the application of aptamers was further extended to target specific delivery of therapeutic compounds. 36 Due to their low immunogenicity, ease of production, freedom for chemical alteration and high target specificity, the scientific community quickly accepted this concept. Since then, the application of aptamers for delivering siRNA has been widely explored.…”

Section: Aptamers As Tools For Sirna Deliverymentioning

confidence: 99%

Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy

et al. 2015

View full text Add to dashboard Cite

Escort aptamers: a delivery service for diagnosis and therapy

Abstract: Hilger have supplied additional expertise. Martin Brechbiel and Brian Moyer provided helpful input on α-particle radiotherapy.

Cited by 150 publications

References 25 publications

Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2

Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2

Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy

Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy

Contact Info

Product

Resources

About